ATRA
Atara·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
MACD Golden Cross
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATRA
Atara Biotherapeutics, Inc.
A pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for solid tumors, hematologic cancers and autoimmune disease
Biological Technology
08/22/2012
10/16/2014
NASDAQ Stock Exchange
153
12-31
Common stock
2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA, 91320
--
Atara Biotherapeutics, Inc., was incorporated in Delaware on August 22, 2012. The company is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop translational therapies for patients with cancer and autoimmune diseases.
Company Financials
EPS
ATRA has released its 2025 Q3 earnings. EPS was reported at -0.32, versus the expected -0.67, beating expectations. The chart below visualizes how ATRA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATRA has released its 2025 Q3 earnings report, with revenue of 3.45M, reflecting a YoY change of -91.41%, and net profit of -4.30M, showing a YoY change of 80.36%. The Sankey diagram below clearly presents ATRA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
